NZ brokers 'great deal' with AbbVie

Posted 14 April 2025 AM

Thousands of New Zealanders will benefit from revamped leukaemia treatment and a new treatment for atopic dermatitis, ulcerative colitis, and Crohn disease thanks to a deal struck between Pharmac and AbbVie that comes into effect from 1 May.

The deal sees AbbVie's Venclexta, already funded in New Zealand for chronic lymphocytic leukaemia, funded for acute myeloid leukaemia when used in combination with low dose cytarabine or Azacitidine Dr Reddy's, for which new funding was also announced. The widened access is expected to benefit 65 people in the first year of funding, rising to around 70 people annually after five years.

To see the whole article, please login